Delivery Order SPE2DB20D7059-SPE2DB25FGRJ9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packages (30 count). This competitive award, valued at $4,145.28 with firm fixed pricing, is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation and represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,758.67 and is scheduled for completion by September 3, 2025. The contract represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,476.51 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with an ultimate completion date of September 10, 2025. This competitive award, issued on September 9, 2025, utilizes firm fixed pricing with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $1,446.12 and has a firm fixed price structure, with an ultimate completion date of September 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $2,508.25. This competitive, non-set-aside award utilizes firm fixed price pricing and carries an ultimate completion date of September 4, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This delivery order, awarded on August 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $1,742.70 under firm fixed price terms. The contract is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-12.5 mg tablets (30-unit dose) valued at $4,139.85. This competitive, firm fixed-price contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, PA, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this...
- The Defense Logistics Agency awarded a delivery order valued at $1,772.81 to AmerisourceBergen Drug Corp for Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a completion deadline of September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $3,631.02 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) on August 11, 2025, with completion due by August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger prime indefinite delivery...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FGRJ9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a ceiling value of $2,026.67. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for ultimate completion on September 11, 2025, with performance and delivery to AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As the prime contractor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support Defense Health Agency and military healthcare operations worldwide. The company's extensive federal contract portfolio demonstrates its established capability to fulfill critical medication requirements across multiple therapeutic domains for military and federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/10/25 |